Study of Golidocitinib and Benmelstobart for relapsed ENKTL lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug combination for people with a rare type of lymphoma (ENKTL) that has come back or not responded after prior treatment. It aims to see if the combination can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with a type of lymphoma called ENKTL.
- You have already tried at least one treatment containing asparaginase, and it stopped working or your cancer came back.
- You are 18 years old or older.
- You are in generally good health, able to take care of yourself (ECOG score 0-2).
- You have at least one measurable tumor that can be seen on scans.
- You have not taken any JAK inhibitor drugs before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs for people with NK/T-cell lymphoma that has come back or not responded to previous treatment. It aims to see if this new mix is safe and effective. You may qualify if your lymphoma returned after certain therapies or didn't respond to them.
This trial tests an oral JAK1 inhibitor called golidocitnib for people with T/NK-cell lymphoma that came back after treatment or didn't respond. The drug works by blocking a signal that helps cancer cells grow.
This trial tests a combination of three drugs (sintilimab, pegaspargase, and GemOx) for people with a type of lymphoma called extranodal NK/T-cell lymphoma (ENKTL) that hasn't been treated before. The goal is to see if this combination helps control the disease.
This trial tests a combination of three drugs (linperlisib, camrelizumab, and pegaspargase) for people with a rare type of lymphoma called ENKTL. It is for patients whose cancer has not responded to treatment or has come back, or who are newly diagnosed with advanced disease.
This trial tests a new drug called golidocitinib added to standard chemotherapy (CHOP) for people newly diagnosed with certain types of T-cell lymphoma. It aims to see if the combination works better than CHOP alone.
This study tests a new combination of three drugs (Golidocitinib, Pegaspargase, and a PD-1 antibody) as the first treatment for people with a rare type of lymphoma called ENKTL. It aims to see if these drugs together can shrink tumors and improve outcomes.
Hear when a new Natural Killer/T-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.